DNMT1
DNA
As of the edition of 20 October 2026, DNMT1 (DNA, UniProt P26358) has 5 drugs tested at it and 10 companies on the list, 2 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P26358
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 29
- Disease areas
- Blood and lymph; Cancer; Immune system; Inherited and neonatal; Urinary and reproductive; Lungs and airways; Digestive system; Skin and connective tissue
- Registered trials of its drugs
- 1,107
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 3 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Azacitidine | Marketed | Phase 4 | Ends 2029 |
| Decitabine | Marketed | Phase 4 | none listed |
| Guadecitabine | Stopped | Phase 3 | none listed |
| NTX-301 | Stopped | Phase 2 | none listed |
| GSK4172239D | Stopped | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 4 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| GSK | Route A |
| Bristol Myers Squibb | Route B |
| Johnson & Johnson | Route B |
The other 7 companies at DNMT1
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at DNMT1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.